Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2018

View Archived Issues

Prothena reorganizing resources to advance neuroscience pipeline

Researchers present novel bifunctional mu-receptor agonist and NPFF receptor antagonist, KGFF-09

Novel experimental model of ZIKV infection with pregnant common marmoset presented

Mouse model of VIPR2 gene copy number variation gives insight into neuropsychiatric disorders

Researchers present new antiviral compounds

EMA accepts European filing for edaravone for ALS

New IDO-1 inhibitor PX-D26116 has improved metabolic stability compared to epacadostat

Actavalon patents AhR agonists for cancer

Wuhan Bowo Biological Technology divulges new influenza and RSV vaccines

Centogene collaborates with Aldeyra Therapeutics in Sjogren-Larsson syndrome

AB Science offers update on European MAA for masitinib in ALS

JCR obtains approval in Brazil to begin phase II trial of JR-141 for Hunter's syndrome

ImmuPharma releases further data analysis from pivotal trial of Lupuzor in SLE

FDA grants orphan drug designation to SNX-5422 for neuroendocrine tumors

Tazemetostat granted U.S. orphan drug designation for chordoma

Arroyo BioSciences' AB-22 granted U.S. orphan drug designation for IPF

FDA approves Cimzia for the treatment of adults with moderate to severe plaque psoriasis

IDMC recommends continuation of phase III study of Zepsyre in small cell lung cancer

FDA grants priority review for gilteritinib NDA in relapsed or refractory AML

REXGEX trial shows importance of immune status for enhanced efficacy with CetuGEX

Chugai seeks Japanese approval for Actemra for cytokine release syndrome

Japanese approval sought for Trelegy Ellipta

Kowa to launch Parmodia in Japan for hyperlipidemia

Researchers discover new targets for lymphoblastic leukemia immunotherapy

Pfizer seeks Japanese approval of dacomitinib for EGFR mutation-positive NSCLC

Phase III IMpower130 study of Tecentriq in NSCLC meets coprimary endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...